# MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
Canonical URL: https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum
Ticker: MGNX
Company: MacroGenics
Source: MacroGenics
Published: 2026-05-14 20:01 EST
Original Source URL: https://ir.macrogenics.com
## Summary

ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside

## Article Body
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside
## Recent Company News
- 2026-05-14 20:01 EST — [MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum](https://biopharmsignal.com/news/MGNX/macrogenics-to-participate-in-the-stifel-2026-virtual-targeted-oncology-forum) — Source: MacroGenics
- 2026-05-13 20:01 EST — [MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation](https://biopharmsignal.com/news/MGNX/macrogenics-reports-first-quarter-2026-financial-results-and-highlights-business-transformation) — Source: MacroGenics
- 2026-05-11 21:20 EST — [MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals](https://biopharmsignal.com/news/MGNX/macrogenics-to-sell-gmp-manufacturing-operations-to-bora-pharmaceuticals) — Source: MacroGenics
- 2026-05-04 11:30 EST — [MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement](https://biopharmsignal.com/news/MGNX/macrogenics-and-sagard-healthcare-partners-enter-into-expanded-zynyzr-royalty-purchase-agreement) — Source: MacroGenics
- 2026-04-08 20:30 EST — [FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study](https://biopharmsignal.com/news/MGNX/fda-removes-partial-clinical-hold-on-macrogenics-linnet-study) — Source: MacroGenics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)